Lexicon Pharmaceuticals, Inc. — 2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter filing; quarterly results are not provided in the supplied filing text.
Business context
Lexicon is a biopharmaceutical company commercializing INPEFA (sotagliflozin) in the United States for heart failure and developing sotagliflozin for type 1 diabetes with chronic kidney disease (CKD) and hypertrophic cardiomyopathy (HCM). Its pipeline also includes LX9211 for neuropathic pain and preclinical obesity candidate LX9851. INPEFA was approved in May 2023 and began shipping in June.
Key financial metrics
| Metric | 2023 | 2022 |
|---|---|---|
| Total revenue | $1.204 million | $0.139 million |
| INPEFA net product revenue | $1.110 million | None |
| Cost of sales | $0.085 million | None |
| Research and development expense | $58.9 million | $52.8 million |
| Selling, general and administrative expense | $114.0 million | $48.1 million |
| Operating loss | $171.8 million | $100.8 million |
| Net loss | $177.1 million | $101.9 million |
| Net loss per share | $0.80 | $0.62 |
| Cash used in operating activities | $161.9 million | $88.9 million |
| Cash, cash equivalents and short-term investments at year-end | $170.0 million | $138.4 million |
| Long-term debt, net | $99.5 million | $48.6 million |
Cost of sales was low relative to product revenue, partly because substantial pre-approval INPEFA raw materials were available at zero recorded cost or had previously been expensed. The company expects this inventory to be used over approximately three years; it estimates cost of goods sold will be below 10% of net product revenue after that inventory is consumed.
Changes versus prior year
- Revenue rose with the launch of INPEFA, but remained small compared with operating costs.
- SG&A increased 137% to $114.0 million, primarily reflecting commercial-launch staffing, marketing and related expenses. R&D increased 12% to $58.9 million.
- Net loss widened by $75.2 million. Interest and other expense rose to $13.1 million from $2.8 million, primarily reflecting Oxford debt financings.
- Operating cash use increased to $161.9 million from $88.9 million. Cash and cash equivalents alone declined to $22.5 million, while short-term investments increased and total cash and investments reached $170.0 million.
- Outstanding common shares increased from 189.2 million to 245.8 million, reflecting 55.3 million shares issued in a 2023 offering and concurrent private placement, among other share activity.
Liquidity, debt and outlook
At December 31, 2023, current assets were $176.5 million and current liabilities were $31.5 million. Oxford term loans had a $99.5 million carrying value and a 12.9% weighted-average interest rate at year-end. The loans are secured by a first lien on substantially all company assets, mature in March 2027, and include minimum-cash and INPEFA-sales covenants. Lexicon reported compliance with debt covenants at year-end.
After year-end, Lexicon reported receiving approximately $242 million net proceeds from a March 2024 private placement of convertible preferred stock. The filing also describes an at-the-market agreement allowing sales of up to $75 million of common stock. Management said available resources and expected revenues would fund currently planned operations for at least 12 months from the report date; it also cautioned that cash generation, expenses and future capital needs could differ from expectations.
Pipeline, management commentary and key risks
- Lexicon is preparing to resubmit the sotagliflozin NDA for type 1 diabetes patients with CKD following FDA discussions. The FDA previously issued a complete response letter in 2019; approval, timing and labeling remain uncertain, including potential DKA warnings.
- A Phase 3 HCM trial of sotagliflozin was being prepared. LX9211 was in a Phase 2b diabetic peripheral neuropathic pain trial; management identifies positive trial results and potential partnering for later-stage development as important. The PHN Phase 2 trial showed evidence of effect but missed its primary statistical endpoint.
- INPEFA commercial adoption, reimbursement, competition from established SGLT2 inhibitors and execution of the launch are significant uncertainties. Three wholesalers accounted for more than 85% of 2023 total revenue, according to the filing.
- The company has a history of losses and an accumulated deficit of $1.8 billion; it expects continued losses and substantial spending. It states that existing resources may not support Phase 3 development of LX9211 without a strategic collaboration or additional financing.
- Commercial supply depends on third parties, including a sole-source U.S. finished-product manufacturer for INPEFA. The company is evaluating backup suppliers. Debt covenants, potential dilution from financing, Invus’s approximately 50% ownership, clinical and regulatory outcomes, and product-liability exposure are additional material risks.
- No material legal proceedings were reported. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor’s report identified accrued clinical-trial R&D expenses as a critical audit matter.
Important facts for investors to verify
- Subsequent INPEFA sales, prescription trends, payer coverage and progress against Oxford’s sales covenants.
- Use of the March 2024 preferred-stock proceeds, conversion conditions and resulting share dilution, as well as any use of the $75 million ATM facility.
- FDA feedback and timing for the type 1 diabetes/CKD NDA resubmission, including the anticipated safety labeling.
- Enrollment, timing and results of the LX9211 Phase 2b trial, the HCM Phase 3 plan, and funding or partnering needs for later-stage development.
- Remaining zero-cost INPEFA inventory, its expected utilization period, and the effect on future reported product margins and cash needs.